Arch Biopartners Announces Non Brokered Private Placement Financing

Arch Biopartners (TSXV:ARCH) a portfolio based biotechnology company, intends to complete a non-brokered private placement offering of up to 2,500,000...

Arch's Anti-Bacterial Candidate to Enter Phase I Trial

Arch Biopartners announced the Cincinnati Veterans Affairs Medical Center oversee a Phase I human trial on the safety and the...